The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Extension of Life-Span by Introduction of Telomerase into Normal Human Cells
Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C.-P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., & Wright, W. E. (1998) · Science · doi:10.1126/science.279.5349.349 · Cited by 4,975
Mitotic kinases as regulators of cell division and its checkpoints
Nigg, E. A. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35048096 · Cited by 1,547
Polo-like kinases and the orchestration of cell division
Barr, F. A., Silljé, H. H. W., & Nigg, E. A. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1401 · Cited by 1,087
Targeting polo-like kinase 1 for cancer therapy
Strebhardt, K., & Ullrich, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1841 · Cited by 841
Lane, H. A., & Nigg, E. A. (1996) · The Journal of cell biology · doi:10.1083/jcb.135.6.1701 · Cited by 690
Aurora-kinase inhibitors as anticancer agents
Keen, N., & Taylor, S. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1502 · Cited by 675
The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1
Lénárt, P., Petronczki, M., Steegmaier, M., Di Fiore, B., Lipp, J. J., Hoffmann, M., Rettig, W. J., Kraut, N., & Peters, J.-M. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.046 · Cited by 653
Self-citationPolo-like kinase (Plk)1 depletion induces apoptosis in cancer cells
Liu, X., & Erikson, R. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031523100 · Cited by 472
Polo-like kinases (Plks) and cancer
Takai, N., Hamanaka, R., Yoshimatsu, J., & Miyakawa, I. (2005) · Oncogene · doi:10.1038/sj.onc.1208272 · Cited by 386
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
Gumireddy, K., Reddy, M. V. R., Cosenza, S. C., Nathan, R. B., Baker, S. J., Papathi, N., Jiang, J., Holland, J., & Reddy, E. P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.009 · Cited by 367
Cited by
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Self-citationTalele, T. T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00472 · Cited by 1,023
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
Current prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 761
Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery
Macůrek, L., Lindqvist, A., Lim, D., Lampson, M. A., Klompmaker, R., Freire, R., Clouin, C., Taylor, S. S., Yaffe, M. B., & Medema, R. H. (2008) · Nature · doi:10.1038/nature07185 · Cited by 710
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Strebhardt, K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3184 · Cited by 653
The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1
Lénárt, P., Petronczki, M., Steegmaier, M., Di Fiore, B., Lipp, J. J., Hoffmann, M., Rettig, W. J., Kraut, N., & Peters, J.-M. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.046 · Cited by 653
Self-citationShared and separate functions of polo-like kinases and aurora kinases in cancer
Lens, S. M. A., Voest, E. E., & Medema, R. H. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2964 · Cited by 597
Kettenbach, A. N., Schweppe, D. K., Faherty, B. K., Pechenick, D., Pletnev, A. A., & Gerber, S. A. (2011) · Science Signaling · doi:10.1126/scisignal.2001497 · Cited by 530
Polo on the Rise—from Mitotic Entry to Cytokinesis with Plk1
Petronczki, M., Lénárt, P., & Peters, J.-M. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.04.014 · Cited by 485
Self-citationPLK1, A Potential Target for Cancer Therapy
Liu, Z., Sun, Q., & Wang, X. (2017) · Translational Oncology · doi:10.1016/j.tranon.2016.10.003 · Cited by 454
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
Gutteridge, R. E. A., Ndiaye, M. A., Liu, X., & Ahmad, N. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0897 · Cited by 406
Rudolph, D., Steegmaier, M., Hoffmann, M., Grauert, M., Baum, A., Quant, J., Haslinger, C., Garin-Chesa, P., & Adolf, G. R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2445 · Cited by 398
Self-citationNuclear PTEN Regulates the APC-CDH1 Tumor-Suppressive Complex in a Phosphatase-Independent Manner
Song, M. S., Carracedo, A., Salmena, L., Song, S. J., Egia, A., Malumbres, M., & Pandolfi, P. P. (2011) · Cell · doi:10.1016/j.cell.2010.12.020 · Cited by 376
Dzamko, N., Deak, M., Hentati, F., Reith, A. D., Prescott, A. R., Alessi, D. R., & Nichols, R. J. (2010) · Biochemical Journal · doi:10.1042/bj20100784 · Cited by 372
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Ciceri, P., Müller, S., O'Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. A., Pallares, G., Picaud, S., Wells, C., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1471 · Cited by 338
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 336
Nucleic acid delivery for therapeutic applications
Gupta, A., Andresen, J. L., Manan, R. S., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113834 · Cited by 331
Mitosis is not a key target of microtubule agents in patient tumors
Komlodi-Pasztor, E., Sackett, D., Wilkerson, J., & Fojo, T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.228 · Cited by 314
Mitosis-targeted anti-cancer therapies: where they stand
Chan, K.-S., Koh, C.-G., & Li, H.-Y. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.148 · Cited by 305
Drug Discovery Targeting Bromodomain-Containing Protein 4
Liu, Z., Wang, P., Chen, H., Wold, E. A., Tian, B., Brasier, A. R., & Zhou, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01761 · Cited by 303
Petronczki, M., Glotzer, M., Kraut, N., & Peters, J.-M. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.03.013 · Cited by 301
Self-citationSur, S., Pagliarini, R., Bunz, F., Rago, C., Diaz, L. A., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813333106 · Cited by 295
Teo, R. D., Hwang, J. Y., Termini, J., Gross, Z., & Gray, H. B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00400 · Cited by 289
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
Athuluri-Divakar, S. K., Vasquez-Del Carpio, R., Dutta, K., Baker, S. J., Cosenza, S. C., Basu, I., Gupta, Y. K., Reddy, M. V. R., Ueno, L., Hart, J. R., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.045 · Cited by 277
Targeting Polo-like Kinase in Cancer Therapy
Degenhardt, Y., & Lampkin, T. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1380 · Cited by 262
Harnessing synthetic lethal interactions in anticancer drug discovery
Chan, D. A., & Giaccia, A. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3374 · Cited by 262
Vimentin Intermediate Filaments as Potential Target for Cancer Treatment
Strouhalova, K., Přechová, M., Gandalovičová, A., Brábek, J., Gregor, M., & Rosel, D. (2020) · Cancers · doi:10.3390/cancers12010184 · Cited by 255
Komlodi-Pasztor, E., Sackett, D. L., & Fojo, A. T. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0999 · Cited by 227
Wolfe, B. A., Takaki, T., Petronczki, M., & Glotzer, M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000110 · Cited by 225
Self-citationSystematic Discovery of TLR Signaling Components Delineates Viral-Sensing Circuits
Chevrier, N., Mertins, P., Artyomov, M. N., Shalek, A. K., Iannacone, M., Ciaccio, M. F., Gat-Viks, I., Tonti, E., DeGrace, M. M., Clauser, K. R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.10.022 · Cited by 179
Present and Future Perspective on PLK1 Inhibition in Cancer Treatment
Chiappa, M., Petrella, S., Damia, G., Broggini, M., Guffanti, F., & Ricci, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903016 · Cited by 120
Wu, J., Ivanov, A. I., Fisher, P. B., & Fu, Z. (2016) · eLife · doi:10.7554/elife.10734 · Cited by 117
CTR1 Silencing Inhibits Angiogenesis by Limiting Copper Entry into Endothelial Cells
Narayanan, G., R., B. S., Vuyyuru, H., Muthuvel, B., & Konerirajapuram Natrajan, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071982 · Cited by 83
PTEN regulates PLK1 and controls chromosomal stability during cell division
Zhang, Z., Hou, S.-Q., He, J., Gu, T., Yin, Y., & Shen, W. H. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1203493 · Cited by 46
Banerjee, S., Zagórska, A., Deak, M., Campbell, D. G., Prescott, A. R., & Alessi, D. R. (2014) · Biochemical Journal · doi:10.1042/bj20140408 · Cited by 32
Lee, Y., Lee, J. S., Lee, K. J., Turner, R. S., Hoe, H.-S., & Pak, D. T. S. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.02.027 · Cited by 27
BICD2 phosphorylation regulates dynein function and centrosome separation in G2 and M
Gallisà-Suñé, N., Sànchez-Fernàndez-de-Landa, P., Zimmermann, F., Serna, M., Regué, L., Paz, J., Llorca, O., Lüders, J., & Roig, J. (2023) · Nature Communications · doi:10.1038/s41467-023-38116-1 · Cited by 26
Twarog, N. R., Low, J. A., Currier, D. G., Miller, G., Chen, T., & Shelat, A. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149439 · Cited by 16
Centromere protection requires strict mitotic inactivation of the Bloom syndrome helicase complex
Fernández-Casañas, M., Karanika, E., Aliyaskarova, U., Olukoga, T., Herbert, A. D., Oliver, A. W., Day, M., Crncec, A., & Chan, K.-L. (2025) · Nature Communications · doi:10.1038/s41467-025-62966-6 · Cited by 5
Schiedel, M., McArdle, D. J. B., Padalino, G., Chan, A. K. N., Forde-Thomas, J., McDonough, M., Whiteland, H., Beckmann, M., Cookson, R., Hoffmann, K. F., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01321 · Cited by 4
Metadata
- Authors
- Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., Grauert, M., Adolf, G. R., Kraut, N., Peters, J.-M., & Rettig, W. J.
- Venue
- Current Biology
- Publisher
- Elsevier BV
- Published
- 2007-02
- Volume
- 17
- Issue
- 4
- Pages
- 316-322
- ISSN
- 0960-9822 (ISSN-L)
- OpenAlex
- W2029108033
- Cited by
- 834
- References
- 21
- FWCI
- 15.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.